Childhood leukemia - New advances and challenges

New England Journal of Medicine

Volumn 351, Issue 6, 2004, Pages 601-603

  Winick, Naomi J ^a   Carroll, William L ^b   Hunger, Stephen P ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; FOLYLPOLYGLUTAMATE SYNTHASE; METHOTREXATE; POLYGLUTAMIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILDHOOD LEUKEMIA; DNA MICROARRAY; EDITORIAL; GENOMICS; HUMAN; IMMUNOPHENOTYPING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; ACUTE LYMPHOCYTIC LEUKEMIA; CHILD; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; NOTE; T LYMPHOCYTE;

CHILD; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PROGNOSIS; T-LYMPHOCYTES;

EID: 3442878415     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe048154     Document Type: Editorial

References (12)

1. Carroll WL, Bhojwani D, Min D-J, et al. Pediatric acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2003;1:102-31.
2. van Dongen JJ, Seriu T, Panzer-Grumayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998;352:1731-8.
3. Donadieu J, Hill C. Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review. Br J Haematol 2001;115:34-45.
4. Coustan-Smith E, Sancho J, Behm FG, et al. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100:52-8.
5. Gorlick R, Goker E, Trippet T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemias. N Engl J Med 1996;335:1041-8.
6. Asselin BL, Shuster JJ, Amylon M, et al. Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) study. Prog Proc Am Soc Clin Oncol 2001;20:367a. abstract.
7. Kaspers GJ, Smets LA, Pieters R, Van Zantwijk CH, Van Wering ER, Veerman AJ. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to anti-metabolites and other drugs: results of an in vitro study. Blood 1995;85:751-6.
8. Kaspers GJ, Veerman AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood 1997;90:2723-9.
9. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000;96:1094-9.
10. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
11. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002;1:133-43.
12. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-42.